True, that’s how it was—the results were provided in connection with the earnings report. Perhaps it is possible that the results are already known but won’t be published until the Q4 report. However, I find that a bit strange from both a regulatory and company communication perspective, if they have the final results but aren’t releasing them to the market. 1) This is significant inside information regarding the company’s value, as a successful study result means it is very likely that nanoenzalutamide will indeed reach the market. This is also the final proof of the technology’s functionality. 2) Why would the company state that the results are coming at the end of the year if they didn’t intend to publish them before the Q4 report?
Hopefully, we will get answers to these questions soon.